• 1
    Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med. 1993;94:64650.
  • 2
    Magaziner J, Simonsick EM, Kashner TM, Hebel JR, Kenzora JE. Predictors of functional recovery one year following hospital discharge for hip fracture: a prospective study. J Gerontol. 1990;45:M1017.
  • 3
    Melton LJ, Atkinson EJ, Cooper C, O'Fallon WM, Riggs BL. Vertebral fractures predict subsequent fractures. Osteoporos Int. 1999;10:21421.
  • 4
    Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA III, Berger M. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res. 2000;15:72139.
  • 5
    Black DM, Arden NK, Palermo L, Pearson J, Cummings SR. Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures. Study of osteoporotic fractures research group. J Bone Miner Res. 1999;14:82128.
  • 6
    Lindsey R, Silverman SL, Cooper C, et al. Risk of new vertebral fracture in the year following a fracture. JAMA. 2001;285:3203.
  • 7
    Ross PD, Davis JW, Epstein RS, Wasnich RD. Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med. 1991;114:91923.
  • 8
    Kado DM, Browner WS, Palermo L, Nevitt MC, Genant HK, Cummings SR. Vertebral fractures and mortality in older women: a prospective study. Arch Intern Med. 1999;159:121520.
  • 9
    Ross PD. Clinical consequences of vertebral fractures. Am J Med. 1997;103:30S43S.
  • 10
    Melton, LJ. III, Kan SH, Frye MA, Wahner HW, O'Fallon WM, Riggs BL. Epidemiology of vertebral fractures in women. Am J Epidemiol. 1989;129:100011.
  • 11
    World Health Organization (WHO Study Group). Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: report of a WHO Study Group. World Health Organ Tech Rep Ser. 1994;843:1129.
  • 12
    Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral efficacy with risedronate therapy (VERT) study group. JAMA. 1999;282:134452.
  • 13
    Jacobsen SJ, Cooper C, Gottlieb MS, Goldberg J, Yahnke DP, Melton LJ, III. Hospitalization with vertebral fracture among the aged: a national population-based study 1986–1989. Epidemiology. 1992;3:5158.
  • 14
    Haczynski J, Jakimiuk A. Vertebral fractures: a hidden problem of osteoporosis. Med Sci Monit. 2001;7:110817.
  • 15
    Majumdar SR, Kim N, Colman I., et al. Incidental vertebral fractures discovered with chest radiography in the emergency department: prevalence, recognition, and osteoporosis management in a cohort of elderly patients. Arch Intern Med. 2005;165:9059.
  • 16
    Gehlbach SH, Bigelow C, Heimisdottir M, May S, Walker M, Kirkwood JR. Recognition of vertebral fracture in a clinical setting. Osteoporos Int. 2000;11:57782.
  • 17
    Genant HK, Wu CY, Van Kuijk C, Nevitt MC. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res. 1993;8:113748.
  • 18
    Altman DG. Practical Statistics For Medical Research. New York, NY: Chapman & Hall; 1991.
  • 19
    Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures: fracture intervention trial research group. Lancet. 1996;348:153541.
  • 20
    Kim N, Rowe BH, Raymond G, et al. Underreporting of vertebral fractures on routine chest radiography. Am J Roentgenol. 2004;182:297300.
  • 21
    Bellantonio S, Fortinsky R, Prestwood K. How well are community-living women treated for osteoporosis after hip fracture. J Am Geriatr Soc. 2001;49:1197204.
  • 22
    American Association of Clinical Endocrinologists. American Association of clinical endocrinologists 2001 medical guidelines for clinical practice for the prevention and management of postmenopausal osteoporosis. Endocrine Pract. 2001;7:294312.
  • 23
    National Osteoporosis Foundation. Physician's Guide to the prevention and treatment of osteoporosis. Available at Accessed July 31, 2004.
  • 24
    Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:143441.
  • 25
    Reid IR, Brown JP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med. 2002;346:65361.